Carisma Therapeutics (CARM) stock retreated on Wednesday after the biopharmaceutical company’s shares underwent a massive 389.42% rally on Tuesday. There was no clear news behind this surge, making an argument for it being a “dead cat bounce” or “sucker’s rally.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Adding to this is the state of Carisma Therapeutics’ operations. The company has laid off a large portion of its staff and is considering strategic alternatives. Management has even warned that a wind-down of the business could be on the horizon.
With the lack of a catalyst and the dire situation Carisma Therapeutics is in, traders shouldn’t be surprised to learn that the stock is falling after yesterday’s rally. This has CARM shares down 35.1% in pre-market trading today. While Carisma Therapeutics has retained a large portion of its gains from yesterday, that could diminish further over the next few days of trading.

Is Carisma Therapeutics Stock a Buy, Sell, or Hold?
TipRanks’ AI analyst, Spark, offers a Neutral (43) rating and no price target for Carisma Therapeutics. Spark cites “significant financial challenges” including “poor financial performance and valuation metrics” as reasons for this rating.
